secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056852
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q1 revenue $1.9M; $391M cash; advances FT819 in SLE, halts FT576 expansion
--------------------------------------------------------------------------------

- Cash, equivalents & investments: $391.1M as of March 31, 2024, including ~$80M offering and ~$20M private placement.
- Q1 revenue $1.9M (collaboration with Ono); GAAP operating expenses $53.0M (R&D $32.1M, G&A $20.9M, incl $11M stock comp).
- First SLE patient treated with FT819 CAR T; dose escalation completed in BCM; FT819 development to focus exclusively on autoimmunity.
- FT522 enrollment opened without conditioning chemotherapy in Phase 1 BCL; IND for autoimmunity planned mid-2024.
- FT576 dose escalation completed in multiple myeloma; company will not advance to Phase 1 dose expansion; evaluating next-gen BCMA candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017024056852/0000950170-24-056852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017024056852/fate-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer